Skip to main content

Table 1 Distributions of patients regarding breast tumor type, ER and PgR expression, HER2 overexpression and age (younger than 55, or older than 54)

From: A model of immunohistochemical differences between invasive breast cancers and DCIS lesions tested on a consecutive case series of 1248 patients

 

Luminal A and B1

Luminal B2

Total

Age

Luminal A and B1

Luminal B2

Total

Distribution of breast cancer patients with positive receptors according to HER2 and age

ER+PgR+

666

172

838

<55

218

69

287

ER+PgR

66

38

104

>54

525

141

666

ERPgR+

11

0

11

Total

743

210

953

Total

743

210

953

Χ2 (p)

13.70 (0.0002)

Χ2(p)

2.34 (0.1260)

Distribution of ductal breast cancer patients according to their steroid receptor phenotype and Ki-67 value

ER+ tumors without HER2

Luminal A (Ki-67 < =14%)

Luminal B1 (Ki-67 > 14%)

Total

Luminal B2

Ki-67 < =14%

Ki-67 > 14%

Total

ER+PgR+

365

301

666

ER+PgR+

49

123

172

ER+PgR

26

40

66

ER+PgR

9

29

38

ERPgR+

6

5

11

ERPgR+

0

0

0

Total

397

346

743

Total

58

152

210

Χ2(p)

5.73 (0.0167)

Χ2 (p)

0.36 (0.5489)

Distribution of ductal breast cancer patients according to their age and other features

Age of Luminal A patients

ER+PgR+

ER+PgR

ERPgR+

Age of HER2 patients

Ki-67 < =14%

Ki-67 > 14%

Total

<55

99

5

4

<55

3

38

41

>54

266

21

2

>54

16

78

94

Total

365

26

6

Total

19

116

135

Χ2(p)

0.77 (0.3789)

 

Χ2 (p)

2.22 (0.1360)

 

Age of Luminal B1 patients

ER+PgR+

ER+PgR

ERPgR+

Age of triple-negative patients

Ki-67 < =14%

Ki-67 > 14%

Total

<55

103

6

1

<55

7

68

75

>54

198

34

4

>54

14

71

85

Total

301

40

5

Total

21

139

160

Χ2(p)

6.00 (0.0143)

 

Χ2 (p)

1.78 (0.1822)

 

Age of Luminal B2 patients

ER+PgR+

ER+PgR

ERPgR+

Age of patients

triple-negative

HER2

Total

<55

65

4

0

<55

75

41

116

>54

107

34

0

>54

85

94

179

Total

172

38

0

Total

160

135

295

Χ2(p)

10.49 (0.0012)

 

Χ2 (p)

8.36 (0.0038)

 
  1. The ER+PgR- phenotype was more common in Luminal B2 in comparison to the pooled Luminal A and B1, in Luminal B1. In Luminal B1 and in B2 ER+PgR- tumors were more common in patients older than 54. HER2-overexpressed patients are often older than 54.